We serve more than 90 countries globally with over 280 million units produced a year. Over 1,600 staff within manufacturing, commercial quality and supply chain functions work in our four manufacturing plants. These are strategically located in Canada, Sweden, France and Brazil.
Our site in Uppsala, Sweden, is focused on our injectable aesthetics portfolio. Our Alby-sur-Chéran, France site serves all markets except the U.S. with topicals—both over-the-counter (OTC) and prescription medicine—and supplies brands such as Differin, Aklief and Epiduo. Our largest production site, at Baie-D’Urfé, Canada, is focused on the global supply of Cetaphil, with additional production of OTC and prescription medicine for the U.S. market. The Latin American market is predominantly served by our site in Hortolândia, Brazil.
SECURING SUPPLY WITH PROVEN RESILIENCE
Approximately 75% of our units sold are produced in-house in four manufacturing facilities. We outsource the production of selected products and formulations (including for key brands such as Dysport, Alluzience and Sculptra). We have a rigorous framework in selecting and partnering with third-party Contract Manufacturing Organizations (CMOs), based on capabilities, capacity, efficiency and contract terms and conditions.
Our operations embrace the most advanced manufacturing technologies to enable innovation at scale and support the rapid growth of our business. We work in an integrated way across the organization to deliver products to customers in a fast, flexible and reliable manner.
INDUSTRY-LEADING SAFETY AND QUALITY TRACK RECORD
Safety and quality are essential pillars of our business conduct, and key to our long-trusted relationships with consumers, patients and healthcare professionals. Our quality and manufacturing processes adhere to a number of local and global laws and regulations. Our four manufacturing sites have successfully passed all material applicable inspections over the past five years.
We measure and monitor patient safety and consumer satisfaction and implement policies and procedures to ensure compliance with applicable regulations.
All of our sites are regularly audited by health authorities (e.g., the U.S. Food and Drug Administration (FDA), Health Canada, the French National Agency for the Safety of Medicines and Health Products (ANSM) and Dekra). In addition, we have earned multiple certifications for all our manufacturing sites, including ISO 14001 and ISO 45001. These certifications demonstrate a commitment to environmental, health and safety management systems.
The key to our approach is continuous improvement. We hold regular quality and safety talks in our factories and continually analyze and learn from incidents at plants inside and outside the company. This has led to a constant and significant reduction in number and frequency of injuries.
Despite the challenges of the COVID-19 crisis, we have been able to keep all manufacturing sites operational to date.An advantage of in-house production is maintaining appropriate control over the sustainability of resource usage. We have made significant progress on our roadmap to reduce water consumption and greenhouse gas emissions across our operations. Three of our four factory sites use 100% renewable electricity from a combination of solar, wind, hydropower, geothermal, biofuel and biomass. Our fourth factory is on track to be powered by 100% renewable electricity by 2024. Currently, more than 99% of renewable electricity is supplied to our four factories, and two are certified Carbon Neutral. Our four factories achieved zero waste-to-landfill ahead of our initial 2020 plan.